Literature DB >> 28903577

A 2-4-Amino Acid Deletion in the V5 Region of HIV-1 Env gp120 Confers Viral Resistance to the Broadly Neutralizing Human Monoclonal Antibody, VRC01.

Shingo Tachibana1, Maho Sasaki1, Takako Tanaka2, Mari Inoue1, Youdiil Ophinni3, Tomohiro Kotaki1, Masanori Kameoka1,3.   

Abstract

The envelope glycoprotein (Env) gp120 of human immunodeficiency virus type 1 (HIV-1) plays a critical role in viral entry into host cells. The broadly neutralizing human monoclonal antibody VRC01, which recognizes the CD4 binding site on gp120, neutralizes more than 90% of HIV-1 isolates. However, some of the CRF01_AE viruses prevalent in Southeast Asia are resistant to VRC01-mediated neutralization. We previously reported that 3 amino acid residues at positions 185, 186, and 197 of gp120 played an important role in the VRC01 resistance of CRF01_AE Env (AE-Env) clones isolated from HIV-infected Thai individuals. However, the VRC01 susceptibility of AE-Env clones was not fully explained by mutations at these 3 residues. In the present study, we examined other factors involved in the acquisition of viral VRC01 resistance. Neutralization tests using lentiviral vectors expressing a series of mutant AE-Env clones revealed that the deletion of 2-4 amino acid residues on the loop structure in the V5 region of gp120 conferred VRC01 resistance to several AE-Env clones. Our results provide novel insights into the mechanisms underlying viral VRC01 resistance.

Entities:  

Keywords:  CRF01_AE; HIV-1; V5 region; VRC01; broadly neutralizing antibody; gp120

Mesh:

Substances:

Year:  2017        PMID: 28903577     DOI: 10.1089/aid.2017.0063

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  4 in total

1.  Characterization of HIV-1 CRF01_AE env Genes Derived from Recently Infected Indonesian Individuals.

Authors:  Maho Sasaki; Tomohiro Kotaki; Siti Qamariyah Khairunisa; Shingo Tachibana; Youdiil Ophinni; Yoshitake Hayashi; Masanori Kameoka
Journal:  AIDS Res Hum Retroviruses       Date:  2019-10-03       Impact factor: 2.205

Review 2.  Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41.

Authors:  Jing Pu; Qian Wang; Wei Xu; Lu Lu; Shibo Jiang
Journal:  Viruses       Date:  2019-08-01       Impact factor: 5.048

3.  Pre-existing resistance in the latent reservoir can compromise VRC01 therapy during chronic HIV-1 infection.

Authors:  Ananya Saha; Narendra M Dixit
Journal:  PLoS Comput Biol       Date:  2020-11-30       Impact factor: 4.475

4.  Adding an Artificial Tail-Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile.

Authors:  Shan Su; Zhenxuan Ma; Chen Hua; Weihua Li; Lu Lu; Shibo Jiang
Journal:  Molecules       Date:  2017-11-20       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.